Probing the Source of an Unstable Impurity and Controlling Its Formation at Release - Adare Pharma Solutions

Adare Pharma Solutions on LinkedIn

Probing the Source of an Unstable Impurity and Controlling Its Formation at Release

Resource Image

APT-76 is an anti-neoplastic agent and currently being developed as an extended-release formulation (enteric coating) for an ongoing early Phase 1 clinical trial. The finished drug product is a capsule filled with mini tablets. Two major issues related to impurities were encountered during the formulation and analytical stages:

Please complete the form below in order to access our resource:

"*" indicates required fields

Personal details

First Name*

Last Name*

Email*

Phone

Company

Name*

Job Title

Other Job Title

Country*

Industry

State/Province*

This field is hidden when viewing the form

Province/Territory*

Timing of Need*

What is your Primary area of Interest? (legacy)*

Focus Area(s)

Service Offering*

This field is hidden when viewing the form

Resource*

This field is hidden when viewing the form

Web Leads*

This field is hidden when viewing the form

LeadSource*

This field is hidden when viewing the form

Campaign Name*

This field is hidden when viewing the form

Download Type

This field is hidden when viewing the form

Download Title

This field is hidden when viewing the form

OwnerId*

Let us know how we can help

Please be specific

<p>By ticking this box, you acknowledge and agree to our GDPR compliance and privacy policy</p>*

By ticking this box, you acknowledge and agree to our GDPR compliance and privacy policy

<p>opt-in for SMS marketing</p>

By ticking this box, you agree to opt-in to SMS Marketing

CAPTCHA

©2025 Adare Pharma Solutions. All rights reserved

Machine Readable Files (cigna.com) Machine Readable Files (anthem.com)